In particular, the expression of IDO increased between primary cutaneous melanoma and negative SLN by median 29.11-fold in five out of seven cases examined (P<0.037), and IL-10 by median 6.37-fold (P<0.047). This evidence concerns the gene IDO1 and cutaneous melanoma.